AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

The research, led by Dr. Daniel Myran, a Canada Research Chair in Social Accountability at the University of Ottawa, followed ...

doidam10 - stock.adobe.com People who land in the ER for psychedelic use are at significantly higher risk of schizophrenia, according to an eye-opening new study. Canadian researchers tracked more ...

Fampridine, used for improving walking in multiple sclerosis, may also enhance working memory in individuals with schizophrenia or depression.

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie ABBV said that its Phase 2 trial ...

People who land in the ER for psychedelic use are at significantly higher risk of schizophrenia, according to an eye-opening new study. Canadian researchers tracked more than 9.2 million people in ...